1. Visual outcome and poor prognostic factors in acute retinal necrosis syndrome
- Author
-
Mora Paolo, Favilla Stefania, Carta Arturo, Gandolfi Stefano, Tagliavini Viola, Zola Marta, Guex-Crosier Yan, and Calzetti Giacomo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual acuity ,Adolescent ,genetic structures ,Visual Acuity ,Eye Infections, Viral ,Acute retinal necrosis syndrome ,Retina ,Young Adult ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Ophthalmology ,medicine ,Humans ,Symptom onset ,Child ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Treatment delay ,Retinal Necrosis Syndrome, Acute ,Retrospective cohort study ,Middle Aged ,Prognosis ,University hospital ,medicine.disease ,eye diseases ,Sensory Systems ,030221 ophthalmology & optometry ,Etiology ,Female ,sense organs ,Acute retinal necrosis ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
To evaluate the impact of selected clinical parameters on the mid-/long-term visual outcome of patients with acute retinal necrosis (ARN) A retrospective cohort study Two University Hospitals (Parma, Italy; Lausanne, Switzerland). Thirty-nine non-HIV patients (39 eyes) with ARN, as confirmed by polymerase chain reaction on intraocular samples. The following potential predictors were tested using linear regression models: age, sex, etiology, best-corrected visual acuity (BCVA) on admission, delay between ARN symptom onset and treatment initiation, and surgery (performed or not). BCVA at the final follow up Thirty-nine of 39 non-HIV patients (22 men and 17 women; mean age, 50 years) diagnosed with ARN were enrolled in the study. Etiologies were: varicella-zoster virus in 25 eyes (64%), herpes simplex viruses in the remaining 14 eyes. The average follow-up duration was 19 ± 13 months. All patients had undergone systemic antivirals; surgery was performed in 16 eyes. The mean delay between onset of visual symptoms and antiviral treatment initiation was 15 ± 31 days (range, 1–180 days). The mean BCVA at baseline was 0.83 ± 0.75 logMAR, while the mean final BCVA was 0.75 ± 0.81 logMAR. Both initial BCVA and treatment delay (TD) were significantly correlated with the final BCVA (p
- Published
- 2020